Vincenza Conteduca
Vincenza Conteduca is an expert in Oncology at Ospedali Riuniti di Foggia (Italy). As of November 2026, ScienceLeadR ranks Vincenza Conteduca in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Vincenza Conteduca has authored 265 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 7 of them ongoing. SLR score: 1,211 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Urology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2011 - 2026University of Foggia - Associate Professor
2021 - 2026
Ospedali Riuniti di Foggia
2025 - 2026
Number : 265
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study. PMID 42972372 — genes, recombination, genetic, homologous recombination, neoplasms, prostate, recombinational dna repair, prostatic neoplasms, therapeutics | BMC Med | 2026 | 0 |
| Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine. PMID 42376796 — neoplasms, prostate, biomarkers, immunotherapy, prostatic neoplasms, precision medicine, therapeutics | Expert Rev Anticancer Ther | 2026 | 2 |
| Serum [-2]proPSA as a Candidate Phenotypic Correlate of Molecular Alterations and Prognostic Marker in Metastatic Castration-Resistant Prostate Cancer. PMID 42959566 — serum, neoplasms, prostate, prostatic neoplasms, castration, therapeutics | Prostate Cancer | 2026 | 0 |
| Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations. PMID 42609124 — genes, recombination, genetic, homologous recombination, neoplasms, prostate, recombinational dna repair, prostatic neoplasms, castration, therapeutics, genes, brca2 | Int J Cancer | 2026 | 1 |
| BRCA Testing in Prostate Cancer: A Histopathologist's Perspective. PMID 42587595 — research design, poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, molecular diagnostic techniques, recombinational dna repair, carcinoma, intraductal, noninfiltrating, nucleic acids, prostatic neoplasms, tissues | Diagnostics (Basel) | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer 2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy | Phase 3 | Recruiting | 2025 |
| Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC) 2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes | Phase 3 | Recruiting | 2025 |
| A Phase 3 Study Comparing BMS 986365 versus Investigator s Choice of Therapy in Participants with Metastatic Castration resistant Prostate Cancer 2024-517422-25-00 — docetaxel, androgens, receptors, androgen, neoplasms, prostate, prostatic neoplasms, castration, therapeutics | Phase 3 | Active not recruiting | 2025 |
| Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide REINFORCE Trial NCT07333066 — docetaxel, neoplasms, prostate, tablets, hormones, prostatic neoplasms, therapeutics | Phase 3 | Recruiting | 2026 |
| APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer a rANdomized trial PERSIAN 2022-501894-37-00 — radiotherapy, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map